Quick Answer
Aurinia Pharmaceuticals Inc. reported Common Stock Shares Outstanding of 132.32 million shares for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed a decrease of -6.1% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: 128.12 million shares | Q2 2021: 128.40 million shares | Q3 2021: 129.57 million shares | Q1 2022: 141.74 million shares | Q2 2022: 141.89 million shares | Q3 2022: 142.11 million shares | Q1 2023: 143.03 million shares | Q2 2023: 143.37 million shares | Q3 2023: 143.61 million shares | Q1 2024: 143.69 million shares | Q2 2024: 142.98 million shares | Q3 2024: 143.11 million shares | Q1 2025: 137.75 million shares | Q2 2025: 132.67 million shares | Q3 2025: 131.84 million shares.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Common Stock Shares Outstanding has grown by 54.8%.
- Historical annual values: Fiscal year 2025: 132.32 million shares | Fiscal year 2024: 140.88 million shares | Fiscal year 2023: 143.83 million shares | Fiscal year 2022: 142.27 million shares | Fiscal year 2021: 141.60 million shares | Fiscal year 2020: 126.70 million shares | Fiscal year 2019: 111.80 million shares | Fiscal year 2018: 85.50 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: